PTPN11 and hepatocellular carcinoma: A previous study observed high expression of SHP2 in both chemoresistant hepatocellular carcinomas (HCCs) and recurrent HCCs derived from patients (Xiang et al., 2017), suggesting a relationship between aberrant SHP2 and chemoresistance.